When you buy through links on our articles, Future and its syndication partners may earn a commission. MRNA technology was thrust into the limelight during the COVID-19 pandemic, but had been in ...
The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.